Search clinical trials for: Lexo

Total 363 results

Neuron, Spain

Recruiting

Effectiveness of Multiple Robotic Gait-Devices for Improving Walking Ability in Subacute Stroke Patients

Stroke | Gait Disorders, Neurologic | Walking

Spain
Eli Lilly and Company
Loxo Oncology, Inc.

Not yet recruiting

A Study of [14C]-LOXO-783 in Healthy Adult Participants

Healthy

United States
LEO Pharma

Completed

LEO 124249 Ointment in the Treatment of Alopecia Areata

Alopecia Areata

United States
Craig Hospital

Recruiting

Transcutaneous Spinal Cord Stimulation to Promote Walking Recovery After Spinal Cord Injury

Spinal Cord Injuries

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
National Taiwan University Hospital
Ministry of Science and Technology, Taiwan; National Taiwan University; National...

Recruiting

A Lego Robot Programming Intervention for Enhancing Older Adult Cognitive Health

Cognitive Inferential Ability

Taiwan
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia

Central Nervous System Neoplasm | Solid Neoplasm | Recurrent Acute Leukemia | Refractory Acute Leukemia | Infantile Fibrosarcoma

United States, Canada
Ruijin Hospital
Cellular Biomedicine Group Ltd.

Completed

A Tolerance Clinical Study on Aerosol Inhalation of Mesenchymal Stem Cells Exosomes In Healthy Volunteers

Healthy

China
LEO Pharma

Terminated

Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis.

Atopic Dermatitis

Germany
LEO Pharma

Completed

A Trial to Investigate the Safety, Tolerability, and Drug Levels in Blood After Single and Multiple Doses of LEO 32731 in Healthy People

Healthy

United Kingdom
LEO Pharma

Completed

A Safety, Tolerability and Pharmacokinetic Study of LEO 29102 in Subjects With Atopic Dermatitis

Atopic Dermatitis

Netherlands
LEO Pharma

Completed

Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic Dermatitis

Atopic Dermatitis

United Kingdom
LEO Pharma

Completed

A Clinical Study to Evaluate the Sensitizing Potential of LEO 43204 Gel

Actinic Keratosis

United States
Loxo Oncology, Inc.
Eli Lilly and Company

Active, not recruiting

A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation (LIBRETTO-321)

Solid Tumor | Medullary Thyroid Cancer

China
Eli Lilly and Company
Loxo Oncology, Inc.

Completed

A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants

Healthy | Hepatic Impairment

United States
Loxo Oncology, Inc.
Eli Lilly and Company

Completed

A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants

Healthy

United States
Eli Lilly and Company
Loxo Oncology, Inc.

Completed

A Study of Selpercatinib (LY3527723) in Healthy Participants

Healthy

United States
Biotronik SE & Co. KG

Completed

Remote Follow-up of Patients Receiving Implantable Cardioverter Defibrillator for Prophylactic Therapy (REFORM)

Ventricular Fibrillation | Ventricular Tachycardia

Germany, Czech Republic
Eli Lilly and Company
Loxo Oncology, Inc.

Recruiting

A Study to Evaluate the Effect of Food on LOXO-783 in Healthy Participants

Healthy

United States
Eli Lilly and Company
Loxo Oncology, Inc.

Active, not recruiting

A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment

Carcinoma, Non-Small-Cell Lung | Thyroid Neoplasms

United States
Eli Lilly and Company
Loxo Oncology, Inc.

No longer available

Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor

Carcinoma, Non-Small-Cell Lung | Thyroid Neoplasms
LEO Pharma

Completed

A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis

Actinic Keratosis

Canada, United States
Yonsei University

Recruiting

Effect of Soft Robotic Exosuit Assistance in Healthy People

Healthy Person

Korea, Republic of
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors

Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Unity Health Toronto

Completed

Effects of External Vibration on Voice Quality in Muscle Tension Dysphonia Patients and Classically Trained Singers

Dysphonia | Singing

Canada
LEO Pharma

Completed

LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris

Psoriasis Vulgaris

Germany
VA Office of Research and Development

Recruiting

Mobile Manual Standing Wheelchair for SCI (MMSW-SCI)

Spinal Cord Injuries

United States
LEO Pharma

Completed

Proof of Concept, Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand Eczema

Hand Eczema

Germany
Peking Union Medical College Hospital
Guidon Pharmaceutics Ltd.

Recruiting

Induced Pluripotent Stem Cell Derived Exosomes for the Treatment of Atopic Dermatitis

Atopic Dermatitis

China
LEO Pharma

Completed

Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use Conditions

Actinic Keratosis

United States
Loxo Oncology, Inc.
Eli Lilly and Company

Available

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Breast Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Colon Cancer | Medullary Thyroid Cancer | Papillary Thyroid Cancer | Other Solid Tumors With Evidence of Activating RET Alteration

Spain, United States, Australia, France, Germany, Israel, Italy, Japan, New Zealand, Poland, Singapore, Switzerland
Loxo Oncology, Inc.
Eli Lilly and Company

Completed

A Study of the Effect of Food on Selpercatinib (LY3527723) in Healthy Participants

Healthy

Singapore
Sihuan Pharmaceutical Holdings Group Ltd.

Completed

Levo Phencynonate Hydrochloride for the Prevention of Seasickness

Motion Sickness

China
PPM Services S.A.

Terminated

Efficacy and Safety Study of GED-0507-34-Levo for Treatment of UC (SEGMENT)

Ulcerative Colitis

United States, Hungary, Slovakia, Italy, Ukraine, Bulgaria, Poland, Latvia, Canada, France
LEO Pharma

Completed

Trial Twice Daily Application of LEO 124249 Ointment 30 mg/g in Treatment of Mild to Moderate Inverse Psoriasis

Inverse Psoriasis

Germany
Tel-Aviv Sourasky Medical Center

Recruiting

Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection

SARS-CoV-2

Israel
LEO Pharma

Completed

LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients

Secondary Hyperparathyroidism

Germany, Poland
LEO Pharma
Quintiles, Inc.

Completed

A Study Evaluating Skin Irritation, Phototoxicity and Safety After Administration of LEO 90105 on Intact Skin of Healthy Japanese Male Subjects

Healthy

Japan
LEO Pharma
Quintiles, Inc.

Completed

A Study Evaluating the Safety of LEO 90105 and Its Vehicle, After Multiple Administration on Intact Skin of Healthy Japanese Male Subjects

Healthy

Japan
LEO Pharma

Completed

An Explorative Trial Evaluating the Effect of LEO 32731 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)

Atopic Dermatitis

Germany
JW Pharmaceutical
LEO Pharma

Completed

Efficacy and Safety of LEO 152020 Tablets for the Treatment of Adults With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada, Czechia, Germany, Poland, Spain, Australia, Japan
JW Pharmaceutical
LEO Pharma

Completed

Trial to Assess the Efficacy and Safety of LEO 152020 in Adult Patients With Cholinergic Urticaria

Cholinergic Urticaria

Germany
LEO Pharma

Completed

An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.

Atopic Dermatitis

United States, Canada, Germany, Poland
LEO Pharma

Completed

A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects

Atopic Dermatitis

United States
LEO Pharma

Completed

LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris

Psoriasis Vulgaris

United States, Canada, Germany, United Kingdom, France, Poland
Eli Lilly and Company
Loxo Oncology, Inc.

Completed

A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function

Healthy | Renal Insufficiency

United States
Loxo Oncology, Inc.
Eli Lilly and Company

Completed

A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants

Healthy

United States
Loxo Oncology, Inc.
Eli Lilly and Company

Recruiting

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432)

Carcinoma, Non-Small-Cell Lung

United States, Denmark, Taiwan, China, Canada, Spain, Japan, Germany, United Kingdom, Brazil, India, Korea, Republic of, Australia, Italy, Norway, Israel, Greece, Turkey, Netherlands, Austria, Belgium, Hong Kong, Poland, Puerto Rico, Russian... and more
LEO Pharma

Completed

Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.

Atopic Dermatitis

United States, Canada, Australia
Balt Extrusion

Completed

Endovascular Treatment of Wide Neck Intracranial Aneurysms With the LEO + Stent : The LEO + II Cohort Study

Intracranial Aneurysm

3

Subscribe